Movement Alert｜WuXi XDC Falls 3.06% in Regular Trading, Morgan Stanley Target Price Cut Continues to Weigh on Sentiment

Market Focus

Jul 08

On July 8, WuXi XDC (02268.HK) declined 3.06% in regular trading, trading at HK$58.65/share, with turnover of approximately HK$152 million.

The decline comes amid continued pressure following Morgan Stanley's recent report cutting the company's target price from HK$83 to HK$80, while lowering earnings forecasts for 2026 through 2030 by approximately 0-7%. The revision was primarily driven by the consolidation of Totient Bio (East Yao Pharma) Q2 financials, which introduced lower gross margins and additional financing costs, compounded by USD depreciation against RMB creating foreign exchange headwinds.

Within the Life Sciences Tools and Services sector, broad-based weakness persisted, with WuXi AppTec down 3.06%, WuXi Biologics down 1.85%, and GenScript Biotech down 1.56%. Despite Daiwa initiating coverage today with a HK$78 target price and naming the stock a top CXO pick, selling pressure in the sector remained dominant.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1189796289"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1189796289\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1189796289?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-08 10:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189796289","market":"us","top_or_hot":-1,"title":"Movement Alert｜WuXi XDC Falls 3.06% in Regular Trading, Morgan Stanley Target Price Cut Continues to Weigh on Sentiment","media":"Market Focus","content":"<p><p>On July 8, WuXi XDC (02268.HK) declined 3.06% in regular trading, trading at HK$58.65/share, with turnover of approximately HK$152 million.</p><p>The decline comes amid continued pressure following Morgan Stanley's recent report cutting the company's target price from HK$83 to HK$80, while lowering earnings forecasts for 2026 through 2030 by approximately 0-7%. The revision was primarily driven by the consolidation of Totient Bio (East Yao Pharma) Q2 financials, which introduced lower gross margins and additional financing costs, compounded by USD depreciation against RMB creating foreign exchange headwinds.</p><p>Within the Life Sciences Tools and Services sector, broad-based weakness persisted, with WuXi AppTec down 3.06%, WuXi Biologics down 1.85%, and GenScript Biotech down 1.56%. Despite Daiwa initiating coverage today with a HK$78 target price and naming the stock a top CXO pick, selling pressure in the sector remained dominant.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜WuXi XDC Falls 3.06% in Regular Trading, Morgan Stanley Target Price Cut Continues to Weigh on Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜WuXi XDC Falls 3.06% in Regular Trading, Morgan Stanley Target Price Cut Continues to Weigh on Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-08 10:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 8, WuXi XDC (02268.HK) declined 3.06% in regular trading, trading at HK$58.65/share, with turnover of approximately HK$152 million.</p><p>The decline comes amid continued pressure following Morgan Stanley's recent report cutting the company's target price from HK$83 to HK$80, while lowering earnings forecasts for 2026 through 2030 by approximately 0-7%. The revision was primarily driven by the consolidation of Totient Bio (East Yao Pharma) Q2 financials, which introduced lower gross margins and additional financing costs, compounded by USD depreciation against RMB creating foreign exchange headwinds.</p><p>Within the Life Sciences Tools and Services sector, broad-based weakness persisted, with WuXi AppTec down 3.06%, WuXi Biologics down 1.85%, and GenScript Biotech down 1.56%. Despite Daiwa initiating coverage today with a HK$78 target price and naming the stock a top CXO pick, selling pressure in the sector remained dominant.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02268","symbol_name":"药明合联","start_time":0,"source_url":"","article_id":"1189796289","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189796289","pubTimestamp":1783478861,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 8, WuXi XDC (02268.HK) declined 3.06% in regular trading, trading at HK$58.65/share, with turnover of approximately HK$152 million.The decline comes amid continued pressure following Morgan...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02268":"药明合联"},"translate_title":"动向提示|药明XDC常规交易跌3.06%大摩目标价下调持续打压人气","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02268":1},"content_text":"On July 8, WuXi XDC (02268.HK) declined 3.06% in regular trading, trading at HK$58.65/share, with turnover of approximately HK$152 million.The decline comes amid continued pressure following Morgan Stanley's recent report cutting the company's target price from HK$83 to HK$80, while lowering earnings forecasts for 2026 through 2030 by approximately 0-7%. The revision was primarily driven by the consolidation of Totient Bio (East Yao Pharma) Q2 financials, which introduced lower gross margins and additional financing costs, compounded by USD depreciation against RMB creating foreign exchange headwinds.Within the Life Sciences Tools and Services sector, broad-based weakness persisted, with WuXi AppTec down 3.06%, WuXi Biologics down 1.85%, and GenScript Biotech down 1.56%. Despite Daiwa initiating coverage today with a HK$78 target price and naming the stock a top CXO pick, selling pressure in the sector remained dominant.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}